Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchAntiandrogensAntiandrogens (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 

Finasteride in hospitalized adult males with COVID-19: A risk factor for severity of the disease or an adjunct treatment: A randomized controlled clinical trial

Zarehoseinzade et al., Medical Journal of The Islamic Republic of Iran, doi:10.47176/mjiri.35.30, Apr 2021
https://c19early.org/zarehoseinzade.html
Mortality 75% improvement lower risk ← → higher risk ICU admission 0% Finasteride  Zarehoseinzade et al.  LATE TREATMENT RCT Is late treatment with antiandrogens beneficial for COVID-19? RCT 80 patients in Iran Lower mortality with antiandrogens (not stat. sig., p=0.36) c19early.org Zarehoseinzade et al., Medical J. The .., Apr 2021 0 0.5 1 1.5 2+ RR
7th treatment shown to reduce risk in September 2020, now with p = 0.000000056 from 49 studies.
No treatment is 100% effective. Protocols combine treatments.
6,200+ studies for 180+ treatments. c19early.org
RCT 80 hospitalized COVID-19 patients in Iran, 40 treated with finasteride, showing no significant differences other than improved oxygen saturation on the 5th day with treatment. There was significantly more patients with diabetes in the control group. 5mg finasteride for 7 days. IRCT20200505047318N1.
risk of death, 75.0% lower, RR 0.25, p = 0.36, treatment 1 of 40 (2.5%), control 4 of 40 (10.0%), NNT 13.
risk of ICU admission, no change, RR 1.00, p = 1.00, treatment 1 of 40 (2.5%), control 1 of 40 (2.5%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zarehoseinzade et al., 30 Apr 2021, Randomized Controlled Trial, Iran, peer-reviewed, 5 authors.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2025 Iran United Kingdom Russia USA Sudan Angola Colombia Kenya Mozambique Pakistan Argentina Vietnam Peru Philippines Spain Brazil Italy France Japan China Uzbekistan Nepal Ethiopia Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Bosnia-Herzegovina Ukraine Côte d'Ivoire Bulgaria Greece Slovakia Singapore Iceland New Zealand Czechia Mongolia Israel Trinidad and Tobago Hong Kong North Macedonia Belarus Qatar Panama Serbia CAR Iran favored high-profit treatments.The average efficacy of treatments was moderate.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2025 Iran United Kingdom Russia USA Sudan Angola Colombia Kenya Mozambique Pakistan Argentina Vietnam Peru Philippines Spain Brazil Italy France Japan China Uzbekistan Nepal Ethiopia Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Bosnia-Herzegovina Côte d'Ivoire Bulgaria Greece Slovakia Malawi Czechia Mongolia Israel Trinidad and Tobago North Macedonia Belarus Qatar Panama Serbia Syria Iran favored high-profit treatments.The average efficacy was moderate.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Finasteride in hospitalized adult males with COVID-19: A risk factor for severity of the disease or an adjunct treatment: A randomized controlled clinical trial
Elham Zarehoseinzade, Abbas Allami, Mehrnoosh Ahmadi, Behzad Bijani, Navid Mohammadi
Medical Journal of The Islamic Republic of Iran, doi:10.47176/mjiri.35.30
Background finasteride mig COVID-19 infe Methods: W patients aged ≥ patients were r drug therapy an and secondary protocol was IR.QUMS.REC significant. Results: We (p= 0.018). Th patients in the f Conclusion: hospitalized m required to help
staff at the B in the study. Conflict of I The authors d
References
Adamowicz, reductase inhi Med Hypothes
Chen, Xu inducible fact transition in
Goren, J, C Mesinkovska N with Reduced Androgenetic, Dermatol
Goren, Mcc, What An insight into
Guan, None, Ni characteristics
Hoffmann, Erichsen, None, Cell
Li, Huang, -19 pa rate of meta-an
Mehta, Mca, None, C immunosuppre
Mikkonen, None, Endocrinol
Moran, Jones, Sharafi, S, outcome of co and over. Int J 14. Hayes AF, P Quantification
Temgoua Mn Belobo, Et, screening of Middle-Incom, Med J
Wambier, Nau, None, Drug
DOI record: { "DOI": "10.47176/mjiri.35.30", "ISSN": [ "1016-1430", "2251-6840" ], "URL": "http://dx.doi.org/10.47176/mjiri.35.30", "author": [ { "affiliation": [], "family": "Zarehoseinzade", "given": "Elham", "sequence": "first" }, { "affiliation": [], "family": "Allami", "given": "Abbas", "sequence": "additional" }, { "affiliation": [], "family": "Ahmadi", "given": "Mehrnoosh", "sequence": "additional" }, { "affiliation": [], "family": "Bijani", "given": "Behzad", "sequence": "additional" }, { "affiliation": [], "family": "Mohammadi", "given": "Navid", "sequence": "additional" } ], "container-title": [ "Medical Journal of The Islamic Republic of Iran" ], "content-domain": { "crossmark-restriction": false, "domain": [ "www.mjiri.iums.ac.ir" ] }, "created": { "date-parts": [ [ 2021, 6, 6 ] ], "date-time": "2021-06-06T11:16:01Z", "timestamp": 1622978161000 }, "deposited": { "date-parts": [ [ 2021, 6, 6 ] ], "date-time": "2021-06-06T11:16:25Z", "timestamp": 1622978185000 }, "indexed": { "date-parts": [ [ 2022, 3, 31 ] ], "date-time": "2022-03-31T02:29:37Z", "timestamp": 1648693777420 }, "is-referenced-by-count": 3, "issn-type": [ { "type": "print", "value": "1016-1430" }, { "type": "electronic", "value": "2251-6840" } ], "issued": { "date-parts": [ [ 2021, 4, 30 ] ] }, "link": [ { "URL": "http://mjiri.iums.ac.ir/article-1-7160-en.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "26714", "original-title": [], "prefix": "10.47176", "published": { "date-parts": [ [ 2021, 4, 30 ] ] }, "published-online": { "date-parts": [ [ 2021, 4, 30 ] ] }, "publisher": "Academic World Research", "reference-count": 0, "references-count": 0, "relation": {}, "resource": { "primary": { "URL": "http://mjiri.iums.ac.ir/article-1-7160-en.html" } }, "score": 1, "short-container-title": [ "mjiri" ], "short-title": [], "source": "Crossref", "subject": [ "General Medicine" ], "subtitle": [], "title": [ "Finasteride in hospitalized adult males with COVID-19: A risk factor for severity of the disease or an adjunct treatment: A randomized controlled clinical trial" ], "type": "journal-article", "update-policy": "http://dx.doi.org/10.47176/mjiri/crossmark_policy" }
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit